HOODS: finding context-specific neighborhoods of proteins, chemicals and diseases

Albert Palleja1,2 and Lars J. Jensen1

1 The Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen N, Denmark
2 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen Ø, Denmark

ABSTRACT

Clustering algorithms are often used to find groups relevant in a specific context; however, they are not informed about this context. We present a simple algorithm, HOODS, which identifies context-specific neighborhoods of entities from a similarity matrix and a list of entities specifying the context. We illustrate its applicability by finding disease-specific neighborhoods of functionally associated proteins, kinase-specific neighborhoods of structurally similar inhibitors, and physiological-system-specific neighborhoods of interconnected diseases. HOODS can be used via a simple interface at http://hoods.jensenlab.org, from where the source code can also be downloaded.

INTRODUCTION

Clustering techniques have been used for decades to divide data into groups of similar entities. In molecular biology, algorithms such as hierarchical clustering, k-means, Markov clustering (MCL) and self-organizing maps have been extensively used to group genes with similar expression patterns (Eisen et al., 1998), to classify medical samples (Alizadeh et al., 2000), to construct protein families (Enright, Van Dongen & Ouzounis, 2002) and to cluster proteins into complexes based on protein interaction data (Krogan et al., 2006). Many authors have used clustered protein networks as a basis onto which they mapped other biological data to discover functional modules and protein complexes (Gavin et al., 2006). The clusters produced by clustering algorithms depend on the chosen parameters, e.g., k in k-means or Inflation in MCL. Yet, for a given biological problem there may be no choice of parameters that simultaneously produces all the desired clusters. The main reason for that is that these algorithms are not informed about the biological context of interest.

To produce context-specific groups of similar entities (neighborhoods), we have developed HOODS. Although it is similar to clustering methods in that it groups similar entities, it is not a clustering algorithm. The goal of clustering is to group entities together so that entities within a cluster are more related to each other than they are to entities...
in other clusters. By contrast, neighborhoods are defined in part by the similarity of the entities and in part by their association to the given context.

In the present paper, we present our method and show that it produces meaningful disease-specific neighborhoods when applied to a network of functionally associated proteins. We tested the performance of our algorithm on this task only to prove that it produces neighborhoods that are significantly better than random; it is not intended to compete with the many existing tools specifically designed for prioritizing disease genes (reviewed in Moreau & Tranchevent, 2012). Our method can be used in any case where the biomedical researcher needs to group entities based on a similarity network given a context. The context can optionally be defined as a weighted context with a score specifying how strongly each entity (e.g., a protein) is associated with the context (e.g., a disease). HOODs is designed to find additional entities from the entities already associated with the context by producing a set of context-specific network neighborhoods. The algorithm is not intended to filter the interactions of protein–protein interaction network that are related to a given context, a problem already addressed by others (Chowdhary et al., 2012; Schaefer et al., 2013). The filtering step of these tools may remove the additional context-specific entities that we want to find with our method. To illustrate the applicability of HOODS, we apply it to two additional, very different biomedical problems: finding kinase-specific neighborhoods of structurally similar inhibitors, and finding disease neighborhoods that relate to specific physiological systems. These examples were chosen because they make use of very different similarity metrics and context scores.

MATERIALS AND METHODS

A simple algorithm to produce context-specific neighborhoods

HOODS identifies groups of related entities starting from two inputs: (1) a similarity matrix of the entities; and (2) a set of scores that associate entities with the context of interest ($s_i$). The algorithm considers every entity in the matrix as a possible seed for a neighborhood. For each seed it goes through the nearest neighbors sorted by similarity and calculates a neighborhood score ($S_j$) at every step (Fig. 1A). This score is defined as follows:

$$S_j = \left( \sum_{i=1}^{j} \frac{s_i}{j} \right)^{\alpha} \times \left( \sum_{i=1}^{j} s_i \right)^{1-\alpha} = \left( \sum_{i=1}^{j} s_i \right) / j^{\alpha}.$$

The parameter $\alpha$ is needed to set how much the user wants to penalize big neighborhoods and it ranges from 0 to 1. In this equation we take into account the label score density in our neighborhoods $\left( \sum_{i=1}^{j} \frac{s_i}{j} \right)$ and the total label score of them $\left( \sum_{i=1}^{j} s_i \right)$. The score is a weighted geometric average from these two components; ideally a neighborhood should have both a high density of labels and a large number of labeled entities.

The algorithm sorts all neighborhoods obtained from all seeds by the neighborhood score and filters out neighborhoods that contain the same set of labeled entities as a higher scoring neighborhood. It also removes neighborhoods that contain no entities that are not already included in any of the higher scoring neighborhoods (Fig. 1B).
Figure 1 Outline of the algorithm. The example illustrates how HOODs calculates the neighborhood scores for each entity and selects a non-redundant subset of neighborhoods (A). For two seeds namely E27 and E9, we show the nearest neighbors sorted by similarity scores. Blue nodes indicate the labeled entities. Looping through the sorted nearest neighbors, the neighborhood score (using the default alpha value of 0.8) varies as both the running sum of the label scores and the neighborhood size change. Notice that the neighborhood score is only computed when the neighborhood contains at least two entities with a label score bigger than 0. The boxes delineate a new possible neighborhood each time a new labeled entity is encountered (these neighborhoods have their score in bold). (B) The algorithm next ranks the neighborhoods by score. To discard redundant neighborhoods, the algorithm loops over the ranked neighborhoods and counts: (i) the number of labeled entities not yet seen in higher ranked neighborhoods (“New labeled entities”), (ii) the number of entities not yet seen in higher ranked neighborhoods (“New entities”), and (iii) the total number of entities from the similarity matrix that have been used to build the set of neighborhoods (“Total entities used”). For instance, one of the neighborhoods obtained using E27 as seed is discarded because it adds no new labeled entities (box and numbers shown in gray).

Disease protein network analysis
A global network of known and predicted interactions among human proteins was downloaded from the STRING database (Szklarczyk et al., 2011). Each interaction comes with an associated confidence score, which we used as the similarity matrix. Links between diseases and proteins were downloaded from the DISEASES database (Pletscher-Frankild et al., 2015), which we used as labels. These links are text-mined from literature and a z-score is calculated for each disease-protein association. Based on these associations, we created disease protein neighborhoods for each disease.

Benchmarking
We used the disease-specific protein neighborhoods produced by HOODS to validate the method and to estimate a value for $\alpha$. To these purposes, we performed leave-one-out cross-validation on a set of disease proteins from OMIM database (Amberger, Bocchini & Hamosh, 2011). To build a benchmark set consisting of actual disease proteins associated to diseases caused by disruptions in more than one protein, we chose 100 proteins encoded by single-gene loci and associated to 32 polygenic diseases in OMIM (Amberger, Bocchini & Hamosh, 2011). These disease associations from OMIM were only used for assessing the quality of the neighborhoods, whereas the text-mining derived labels described in
the previous section were used to define the neighborhoods. To prove that our method is
not biased by the fact that disease proteins are more studied than others, we repeated the
leave-one-out cross-validation test choosing a random of the other 31 diseases as labels.
We went through the top ranked neighborhoods again counting the proteins encountered
before finding the left out proteins for the random disease label assigned, including all
the proteins in the neighborhood containing them. To choose the random label, the only
restriction was that both disease labels could not affect the same physiological system.

Kinase inhibitor analysis
To analyze kinase inhibitors, we started from the activity screen of 178 compounds against
300 kinases published by Anastasiadis et al. (2011). We used the Tanimoto coefficients as
similarity matrix among the inhibitors. These were calculated using Open Babel v2.2.3
with PF2 fingerprints (O’Boyle et al., 2011). We used as labels the percent inhibition caused
by the compounds on a given kinase. Based on these we created compound neighborhoods
for each of the resulting in 300 sets of labels.

Disease network analysis
The disease network of Goh et al. (2007) is derived from OMIM. The interactions in
the network represent shared genes, and we thus used the number of shared genes
between each pair of diseases as the similarity matrix. The diseases had been classified
into 22 categories based on which physiological system they affect. The label scores of
all the diseases belonging to a category were set to 1 and used to produce a set of disease
neighborhoods for each of the 22 physiological systems.

RESULTS AND DISCUSSION
Validation of disease-specific protein neighborhoods produced by HOODS
We first used HOODS to identify disease-related protein neighborhoods using the
human protein network from STRING (Szklarczyk et al., 2011) as matrix and text-mined
disease–protein associations from DISEASES (Pletscher-Frankild et al., 2015) as labels.
To validate our method and to estimate a value for \( \alpha \) we performed leave-one-out
cross-validation on a set of the 100 proteins encoded by single-gene loci associated to
32 polygenic diseases in OMIM (Amberger, Bocchini & Hamosh, 2011). Going through the
ranked neighborhoods, we counted the total number of unique proteins encountered
before finding the left out protein, including all the proteins in the neighborhood
containing it (Fig. 1B). HOODS showed similar, good performance for \( \alpha \) ranging from
0.6 to 1.0 (Fig. 2). We chose 0.8 as the default value for \( \alpha \) because it is both the middle of
this range and the value that gave the best performance, recovering 80 of the 100 proteins
from the OMIM benchmark set among the first 100 proteins used to build the networks
(Fig. 2). To show that the good performance is not purely due to disease proteins being
more studied, we redid the leave-one-out cross-validation choosing a random of the other
31 diseases as labels. This recovered only 1 protein of the 100 proteins.
Figure 2  **Validation of HOODS and estimation of alpha parameter.** The bar chart shows the number of disease proteins correctly recovered before using 25, 50 or 100 proteins from the similarity matrix in the leave-one-out cross-validation of the method. The error bars represent the 95% confidence interval according to the Binomial distribution when using 100 proteins from the similarity matrix. For alpha values between 0.6 and 1, we observe similar performance, with 0.8 being the optimum.

As an example of the disease neighborhoods we chose the Leigh disease, which is a rare neurometabolic disorder caused by mutations in genes encoding subunits of the mitochondrial respiratory chain or assembly factors of respiratory chain complexes ([Diaz et al., 2011](#)). The highest scoring neighborhood with more than one protein not associated to the disease contains 12 proteins, 10 of which are labeled with the disease: 8 assembly factors of cytochrome c oxidase (COX) ([Diaz et al., 2011](#)); one mitochondrial COX subunits ([Diaz et al., 2011](#)); one mitochondrial ATP synthase subunit ([Kucharczyk, Rak & di Rago, 2009](#)). In addition, there are two proteins that were not labeled with the disease, namely MT-CO3, and FDXR ([Fig. 3A](#)). MT-CO3 is one of three mitochondrial COX subunits and has already been linked to Leigh disease ([Tiranti et al., 2000](#)); the text mining strategy failed to find this link, but HOODS was able to recover it. FDXR is a new candidate protein that is likely to be involved in Leigh disease considering their role in the biosynthesis and covalent attachment of the prosthetic heme A group of COX ([Barros & Tzagoloff, 2002; Moraes, Diaz & Barrientos, 2004; Diaz et al., 2011](#)).

**Kinase-specific inhibitor neighborhoods**

To test if HOODS can also be applied to chemoinformatics problems, we used it to group kinase inhibitor with similar chemical structure that target a given kinase. Figure 3B shows the results obtained using the inhibition data for the tyrosine kinase VEGFR2, the malfunction of which is related to angiogenesis-dependent cancers such as renal
Figure 3 Example neighborhoods produced by HOODS. (A) A protein neighborhood related to Leigh disease. (B) Two neighborhoods of kinase inhibitors that target VEGFR2, and (C) Two disease neighborhoods of related eye diseases. In all examples, the labeled entities are shown in blue. For the disease protein neighborhood and the two kinase inhibitor neighborhoods, the molecular structures are shown within the nodes where available. The widths of the edges represent the relative similarities, which are based on the STRING interaction scores between the proteins, the Tanimoto coefficients between the chemical compounds, and the number of genes shared between the diseases, respectively.
cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) (Demetri et al., 2006; Motzer et al., 2007). We obtained two neighborhoods of VEGFR2 inhibitors. The first comprises Sunitinib and the structurally similar compound SU 11652. Sunitinib targets multiple receptor tyrosine kinases including the VEGFR kinases and is used to treat RCC and imatinib-resistant GIST (Demetri et al., 2006; Motzer et al., 2007). The second neighborhood contains six compounds: Staurosporine, three Staurosporine derivates and two other compounds similar to Staurosporine (Lestaurtinib and KT 5720). The Staurosporine-like compounds are known for their high promiscuity, i.e., they inhibit many kinases.

**Physiological system-specific disease neighborhoods**

Mutations in genes are the molecular causes of many human diseases. Because many genes are involved in multiple diseases, the network of human diseases is highly interconnected (Vidal, Cusick & Barabasi, 2011). We tested the ability of HOODS to identify neighborhoods of diseases affecting certain physiological systems within the disease network published by Goh et al. (2007). To illustrate the results, we show two of the highest scoring neighborhoods for ophthalmological diseases (Fig. 3C). The first contains 13 ophthalmological diseases. The second neighborhood contains 9 ophthalmological, one skeletal (morning glory disc anomaly) and one developmental disease (Peter’s anomaly). Although the latter two were not classified as ophthalmological diseases, they are both eye diseases affecting the optic nerve and the cornea, respectively.

**Usage of HOODS**

To enable the usage of HOODS in an easy way without programming skills needed, we built a simple interface at http://hoods.jensenlab.org. This interface allows the users to upload their proteins of interest from human or budding yeast as labels and use the human or budding yeast protein interactions from STRING (Szklarczyk et al., 2011) as similarity matrix. However, the interface it is not restricted to work only with human and yeast proteins, the users can also upload their own labels and customized similarity matrices from other organisms or from other biomedical fields. For analysis of large datasets, we recommend that users download the program from the website and run it on their own computers.

**CONCLUSIONS**

We have presented a new algorithm, HOODS, for identifying context-specific neighborhoods. The algorithm produces meaningful results for data from a variety of biomedical disciplines, which highlights its applicability within bioinformatics, chemoinformatics, and medical informatics alike. HOODS is available from http://hoods.jensenlab.org, where it can be either used through a simple web interface or downloaded for local installation.

**ACKNOWLEDGEMENTS**

We thank Sune Pletscher-Frankild for early access to the disease–protein associations from the DISEASES database.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was in part funded by the Novo Nordisk Foundation Center for Protein Research [NNF14CC0001], by the TARGET research initiative (Danish Strategic Research Council [0603-00484B]), and by the National Institutes of Health [U54 CA189205-01]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Novo Nordisk Foundation Center for Protein Research: NNF14CC0001.
TARGET research initiative (Danish Strategic Research Council): 0603-00484B.
National Institutes of Health: U54 CA189205-01.

Competing Interests
The authors declare that there are no competing interests.

Author Contributions
• Albert Palleja performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
• Lars J. Jensen conceived and designed the experiments, analyzed the data, wrote the paper, reviewed drafts of the paper.

REFERENCES
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511 DOI 10.1038/35000501.
Amberger J, Bocchini C, Hamosh A. 2011. A new face and new challenges for Online Mendelian Inheritance in Man (OMIM(R)). Human Mutation 32:564–567 DOI 10.1002/humu.21466.
Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. 2011. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology 29:1039–1045 DOI 10.1038/nbt.2017.
Barros MH, Tzagoloff A. 2002. Regulation of the heme A biosynthetic pathway in Saccharomyces cerevisiae. FEBS Letters 516:119–123 DOI 10.1016/S0014-5793(02)02514-0.
Chowdhary R, Tan SL, Zhang J, Karnik S, Bajic VB, Liu JS. 2012. Context-specific protein network miner–an online system for exploring context-specific protein interaction networks from the literature. PLoS ONE 7:e34480 DOI 10.1371/journal.pone.0034480.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X,
Baum CM, Casali PG. 2006. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet 368:1329–1338 DOI 10.1016/S0140-6736(06)69446-4.

Diaz F, Kotarsky H, Fellman V, Moraes CT. 2011. Mitochondrial disorders caused by mutations in respiratory chain assembly factors. Seminars in Fetal and Neonatal Medicine 16:197–204 DOI 10.1016/j.siny.2011.05.004.

Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 95:14863–14868 DOI 10.1073/pnas.95.25.14863.

Enright AJ, Van Dongen S, Ouzounis CA. 2002. An efficient algorithm for large-scale detection of protein families. Nucleic Acids Research 30:1575–1584 DOI 10.1093/nar/30.7.1575.

Gavin A-C, Aloy P, Grandi P, Krause R, Boesche M, Marzioch M, Rau C, Jensen LJ, Bastuck S, Dümpelfeld B, Edelmann A, Heurtier M-A, Hoffman V, Hoefert C, Klein K, Hudak M, Michon A-M, Schelder M, Schirle M, Remor M, Rudi T, Hooper S, Bauer A, Bouwmeester T, Casari G, Drewes G, Neubauer G, Rick JM, Kuster B, Bork P, Russell RB, Superti-Furga G. 2006. Proteome survey reveals modularity of the yeast cell machinery. Nature 440:631–636 DOI 10.1038/nature04532.

Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. 2007. The human disease network. Proceedings of the National Academy of Sciences of the United States of America 104:8685–8690 DOI 10.1073/pnas.0701361104.

Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, Ignatchenko A, Li J, Pu S, Datta N, Tikuisis AP, Punna T, Peregrín-Alvarez JM, Shakes M, Zhang X, Davey M, Robinson MD, Paccanaro A, Bray JE, Sheung A, Beattie B, Richards DP, Canadien V, Lalev A, Mena F, Wong P, Starostine A, Canete MM, Vlasblom J, Wu S, Orsi C, Collins SR, Chandran S, Haw R, Rilstone JJ, Gomi K, Thompson NJ, Musso G, St Onge P, Ghanny S, Lam MHY, Butland G, Altat-UL AM, Kanaya S, Shilatifard A, O'Shea E, Weissman JS, Ingles CJ, Hughes TR, Parkinson J, Gerstein M, Wodak SJ, Emili A, Greenblatt JF. 2006. Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 440:637–643 England DOI 10.1038/nature04670.

Kucharczyk R, Rak M, di Rago JP. 2009. Biochemical consequences in yeast of the human mitochondrial DNA 8993T>C mutation in the ATPase6 gene found in NARP/MLLS patients. Biochimica et Biophysica ACTA/General Subjects 1793:817–824 DOI 10.1016/j.bbamcr.2009.02.011.

Moraes CT, Diaz F, Barrientos A. 2004. Defects in the biosynthesis of mitochondrial heme c and heme a in yeast and mammals. Biochimica et Biophysica ACTA/General Subjects 1659:153–159 DOI 10.1016/j.bbamcr.2004.09.002.

Moreau Y, Tranchevent LC. 2012. Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nature Reviews Genetics 13:523–536 DOI 10.1038/nrg3253.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczyliuk C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 356:115–124 DOI 10.1056/NEJMoa065044.

O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. 2011. Open Babel: an open chemical toolbox. Journal of Cheminformatics 3:33 DOI 10.1186/1758-2946-3-33.
Pletscher-Frankild S, Palleja A, Tsafou K, Binder JX, Jensen LJ. 2015. DISEASES: text mining and data integration of disease-gene associations. Methods 74:83–89 DOI 10.1016/j.ymeth.2014.11.020.

Schaefer MH, Lopes TJ, Mah N, Shoemaker JE, Matsuoka Y, Fontaine JF, Louis-Jeune C, Eisfeld AJ, Neumann G, Perez-Iratxeta C, Kawaoka Y, Kitano H, Andrade-Navarro MA. 2013. Adding protein context to the human protein-protein interaction network to reveal meaningful interactions. PLoS Computational Biology 9:e1002860 DOI 10.1371/journal.pcbi.1002860.

Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ, Mering Cv. 2011. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Research 39:D561–D568 DOI 10.1093/nar/gkq973.

Tiranti V, Corona P, Greco M, Taanman JW, Carrara F, Lamantea E, Nijtmans L, Uziel G, Zeviani M. 2000. A novel frameshift mutation of the mtDNA COIII gene leads to impaired assembly of cytochrome c oxidase in a patient affected by Leigh-like syndrome. Human Molecular Genetics 9:2733–2742 DOI 10.1093/hmg/9.18.2733.

Vidal M, Cusick ME, Barabasi AL. 2011. Interactome networks and human disease. Cell 144:986–998 DOI 10.1016/j.cell.2011.02.016.